Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A0B65S3
Mon, 12.07.2021
PAION AG
First Berlin Equity Research hat ein Research Update zu PAION AG (ISIN:
DE000A0B65S3) veröffentlicht. Analyst Simon Scholes bestätigt seine
BUY-Empfehlung und senkt das Kursziel von EUR 4,90 auf EUR 4,10.
Zusammenfassung:
Im bisherigen Jahresverlauf haben PAIONs Partner das ultrakurz wirksame
Sedativum/Anästhetikum Remimazolam in [ … ]
Fri, 09.07.2021
PAION AG
PAION ANNOUNCES THAT NMPA ACCEPTS SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BESYLATE IN GENERAL ANESTHESIA BY CHINESE LICENSEE YICHANG HUMANWELL
Aachen (Germany), 09 July 2021 - The specialty pharma company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that its Chinese remimazolam licensee Yic [ … ]
Tue, 29.06.2021
PAION AG
PAION RECEIVES UK MHRA APPROVAL OF BYFAVO(R) (REMIMAZOLAM) FOR PROCEDURAL SEDATION
Aachen (Germany), 29 June 2021 - The specialty pharma company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved Byfavo(R) (remimazolam besyl [ … ]
Wed, 12.05.2021
PAION AG
PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2021
- Remimazolam launches in the U.S. and South Korea in the first quarter of 2021
- EU market approval received for remimazolam in procedural sedation in March 2021
- Good progress in commercialization of remimazolam in the U.S., Japan, China and South Korea through our pa [ … ]
Wed, 07.04.2021
PAION AG
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.PAION AG ANNOUNCES SUCCESSFUL COMPLETION OF CAPITAL INCREASE WITH SUBSCRIPTION RIGHTS
- All new shares were placed
- Subscription rate of 92.41%
Aachen (Germany), 07 April 2021 - [ … ]
Wed, 07.04.2021
PAION AG
PAION ANNOUNCES PRODUCT LAUNCH OF BYFAVOTM (REMIMAZOLAM) IN SOUTH KOREA BY HANA PHARM
Aachen (Germany), 07 April 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that Hana Pharm, remimazolam licensee for South Korea, informed PAION about the launch of ByfavoTM (remimazol [ … ]
Tue, 30.03.2021
PAION AG
PAION AG REPORTS ON SUCCESSFUL FISCAL YEAR 2020
- Significant progress with remimazolam: Market approvals in the U.S., Japan, South Korea and China; launches conducted in Japan and China in 2020, in the U.S. in the beginning of 2021
- EU market approval received for remimazolam in procedural sedation in 2021
- Partners in China & Japan r [ … ]
Tue, 12.01.2021
PAION AG
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
- PAION in-licenses exclusive rights to commercialize GIAPREZA(TM) and XERAVA(TM) throughout Europe
- La Jolla Pharmaceutical Company to receive USD 22.5 million upfront payment, up to USD 109.5 mi [ … ]
Tue, 12.01.2021
PAION AG
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
- PAION in-licenses exclusive rights to commercialize GIAPREZA(TM) and XERAVA(TM) throughout Europe
- La Jolla Pharmaceutical Company to receive USD 22.5 million upfront payment, up to USD 109.5 mi [ … ]
Thu, 07.01.2021
PAION AG
PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM (BYFAVOTM) IN GENERAL ANESTHESIA IN SOUTH KOREA
Aachen (Germany), 07 January 2021 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) announces that Hana Pharm, remimazolam licensee for South Korea, today informed PAION that South Ko [ … ]